- ISIN
- US67080T1088
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Feb 4, 2022
Highlights
- Market Cap
- $387.04M
- Enterprise Value
- $361.91M
- EPS (TTM)
- -$1.22
- EBITDA (TTM)
- -$22.01M
- Year Range
- $5.55 - $16.64
- Target Price
- $10.00
- ROA (TTM)
- -106.94%
- ROE (TTM)
- -191.00%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
NVCT Performance Chart
Nuvectis Pharma Inc (NVCT) is up 118.9% since the beginning of the year. At $17 per share, NVCT is trading just below its 52-week high of $17.
Loading charts...
Returns By Period
Nuvectis Pharma Inc (NVCT) has returned 118.94% so far this year and 103.32% over the past 12 months.
Nuvectis Pharma Inc
- 1D
- 19.61%
- 1M
- 59.71%
- YTD
- 118.94%
- 6M
- 100.12%
- 1Y
- 103.32%
- 3Y*
- -0.83%
- 5Y*
- —
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.64%
- 1Y
- 25.22%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
NVCT Monthly Returns History
Based on dividend-adjusted daily data since Feb 4, 2022, NVCT's average daily return is +0.33%, while the average monthly return is +4.93%. At this rate, an investment would double in approximately 1.2 years.
Historically, 53% of months were positive and 47% were negative. The best month was Feb 2022 with a return of +73.9%, while the worst month was Nov 2024 at -32.5%. The longest winning streak lasted 7 consecutive months, and the longest losing streak was 5 months.
On a daily basis, NVCT closed higher 49% of trading days. The best single day was Feb 7, 2022 with a return of +144.6%, while the worst single day was Nov 14, 2024 at -46.3%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 7.42% | 9.25% | -12.75% | 10.74% | 13.90% | 69.54% | 118.94% | ||||||
| 2025 | 24.95% | -1.04% | 46.04% | 1.94% | -5.52% | -20.62% | -6.83% | -5.75% | -8.23% | 11.46% | -7.00% | 20.99% | 39.56% |
| 2024 | -12.59% | 35.39% | -16.92% | -25.85% | 11.35% | -6.50% | 0.32% | 9.61% | -9.63% | 18.76% | -32.53% | 7.34% | -35.13% |
| 2023 | 32.27% | 15.22% | 14.70% | 12.89% | 18.24% | -8.74% | -12.02% | 1.85% | -9.92% | -30.57% | -5.03% | -1.88% | 11.20% |
| 2022 | 73.92% | 7.86% | 28.21% | 58.21% | -25.48% | -21.43% | -7.95% | -12.47% | -4.37% | 8.41% | 2.04% | 89.87% |
Benchmark Metrics
Nuvectis Pharma Inc has an annualized alpha of 114.95%, beta of 0.44, and R2 of 0.00 versus S&P 500 Index. Calculated based on daily prices since February 04, 2022.
- This stock captured 28.66% of S&P 500 Index gains and tended to rise during its downturns (downside capture of -226.60%) - a profile typical of hedging or uncorrelated assets.
- Beta of 0.44 may look defensive, but with R2 of 0.00 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
- R2 of 0.00 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 114.95%
- Beta
- 0.44
- R²
- 0.00
- Upside Capture
- 28.66%
- Downside Capture
- -226.60%
Return for Risk
Risk / Return Rank
NVCT ranks 82 for risk / return — in the top 82% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Nuvectis Pharma Inc (NVCT) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| NVCT | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.34 | ||
| Sortino ratioReturn per unit of downside risk | -0.26 | ||
| Omega ratioGain probability vs. loss probability | 1.29 | 1.37 | -0.08 |
| Calmar ratioReturn relative to maximum drawdown | 3.27 | 2.78 | +0.49 |
| Martin ratioReturn relative to average drawdown | 6.10 | 12.44 | -6.34 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Nuvectis Pharma Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Nuvectis Pharma Inc was 77.89%, occurring on Dec 20, 2024. The portfolio has not yet recovered.
The current Nuvectis Pharma Inc drawdown is 19.13%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2024 bear market2024 | -77.89%Dec 2024 | 2y 7mo | — | 4y 1moMay 2022 - now |
Bear market2022 | -33.74%Mar 2022 | 6d | 16d | 22dMar 2022 - Apr 2022 |
Bear market2022 | -31.95%Feb 2022 | 6d | 22d | 28dFeb 2022 - Mar 2022 |
Bear market2022 | -21.87%May 2022 | 1d | 3d | 4dMay 2022 - May 2022 |
Bear market2022 | -17.72%Feb 2022 | 0s | 3d | 3dFeb 2022 - Feb 2022 |
Drawdown Indicators
| NVCT | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -77.89% | -56.78% | -21.11% |
Max Drawdown (1Y)Largest decline over 1 year | -31.76% | -9.10% | -22.66% |
Max Drawdown (3Y)Largest decline over 3 years | -73.33% | -18.90% | -54.43% |
Max Drawdown (5Y)Largest decline over 5 years | — | -25.43% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -19.13% | -1.80% | -17.33% |
Average DrawdownAverage peak-to-trough decline | -53.14% | -10.71% | -42.43% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 17.01% | 2.03% | +14.98% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Nuvectis Pharma Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Nuvectis Pharma Inc is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for NVCT in comparison with other companies in the Biotechnology industry. Currently, NVCT has a P/B value of 27.2. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with NVCT
Add Nuvectis Pharma Inc to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with NVCT